Matches in Nanopublications for { ?s ?p "[We have recently shown that a novel, reversible MetAP2 inhibitor, A-357300, significantly inhibits CHP-134-derived neuroblastoma s.c. xenograft growth rate with a treatment-to-control (T/C) ratio at day 24 of 0.19 (P < 0.001) without toxicity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- assertion description "[We have recently shown that a novel, reversible MetAP2 inhibitor, A-357300, significantly inhibits CHP-134-derived neuroblastoma s.c. xenograft growth rate with a treatment-to-control (T/C) ratio at day 24 of 0.19 (P < 0.001) without toxicity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[We have recently shown that a novel, reversible MetAP2 inhibitor, A-357300, significantly inhibits CHP-134-derived neuroblastoma s.c. xenograft growth rate with a treatment-to-control (T/C) ratio at day 24 of 0.19 (P < 0.001) without toxicity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP863699.RAlt_pML_diS0STMYSverc6z0oq_3nZuLsuUwl7l1jMLs130_assertion description "[We have recently shown that a novel, reversible MetAP2 inhibitor, A-357300, significantly inhibits CHP-134-derived neuroblastoma s.c. xenograft growth rate with a treatment-to-control (T/C) ratio at day 24 of 0.19 (P < 0.001) without toxicity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP863699.RAlt_pML_diS0STMYSverc6z0oq_3nZuLsuUwl7l1jMLs130_provenance.
- assertion description "[We have recently shown that a novel, reversible MetAP2 inhibitor, A-357300, significantly inhibits CHP-134-derived neuroblastoma s.c. xenograft growth rate with a treatment-to-control (T/C) ratio at day 24 of 0.19 (P < 0.001) without toxicity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[We have recently shown that a novel, reversible MetAP2 inhibitor, A-357300, significantly inhibits CHP-134-derived neuroblastoma s.c. xenograft growth rate with a treatment-to-control (T/C) ratio at day 24 of 0.19 (P < 0.001) without toxicity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP978744.RAhclY03d8AnAiDTNynEPoaLjx4ydbTFp6BFiYfXuRGuM130_assertion description "[We have recently shown that a novel, reversible MetAP2 inhibitor, A-357300, significantly inhibits CHP-134-derived neuroblastoma s.c. xenograft growth rate with a treatment-to-control (T/C) ratio at day 24 of 0.19 (P < 0.001) without toxicity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978744.RAhclY03d8AnAiDTNynEPoaLjx4ydbTFp6BFiYfXuRGuM130_provenance.
- NP978758.RAvt0td33K6KkPW6yaKc_2RfBoDYrJvqzt4_IdbXf3i5c130_assertion description "[We have recently shown that a novel, reversible MetAP2 inhibitor, A-357300, significantly inhibits CHP-134-derived neuroblastoma s.c. xenograft growth rate with a treatment-to-control (T/C) ratio at day 24 of 0.19 (P < 0.001) without toxicity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978758.RAvt0td33K6KkPW6yaKc_2RfBoDYrJvqzt4_IdbXf3i5c130_provenance.
- NP488823.RAjmxCseRqwfYAQ1SRA4ZAChQ_ZoZPx4B0uqwXB0eD5aU130_assertion description "[We have recently shown that a novel, reversible MetAP2 inhibitor, A-357300, significantly inhibits CHP-134-derived neuroblastoma s.c. xenograft growth rate with a treatment-to-control (T/C) ratio at day 24 of 0.19 (P < 0.001) without toxicity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP488823.RAjmxCseRqwfYAQ1SRA4ZAChQ_ZoZPx4B0uqwXB0eD5aU130_provenance.
- NP488824.RAijvK8ePTzQWXC482N_nqVpqaz2N9s4vZODCJVc25Wgk130_assertion description "[We have recently shown that a novel, reversible MetAP2 inhibitor, A-357300, significantly inhibits CHP-134-derived neuroblastoma s.c. xenograft growth rate with a treatment-to-control (T/C) ratio at day 24 of 0.19 (P < 0.001) without toxicity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP488824.RAijvK8ePTzQWXC482N_nqVpqaz2N9s4vZODCJVc25Wgk130_provenance.
- NP488820.RAF51p_WPwZ8exvr5GOlJenkBQnpkWBuab5nDF8erAeSI130_assertion description "[We have recently shown that a novel, reversible MetAP2 inhibitor, A-357300, significantly inhibits CHP-134-derived neuroblastoma s.c. xenograft growth rate with a treatment-to-control (T/C) ratio at day 24 of 0.19 (P < 0.001) without toxicity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP488820.RAF51p_WPwZ8exvr5GOlJenkBQnpkWBuab5nDF8erAeSI130_provenance.
- NP488818.RA_hROlrRq9-PK5AdKIjGmzFb_kERYleTTJ_djjTu1lII130_assertion description "[We have recently shown that a novel, reversible MetAP2 inhibitor, A-357300, significantly inhibits CHP-134-derived neuroblastoma s.c. xenograft growth rate with a treatment-to-control (T/C) ratio at day 24 of 0.19 (P < 0.001) without toxicity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP488818.RA_hROlrRq9-PK5AdKIjGmzFb_kERYleTTJ_djjTu1lII130_provenance.
- NP863646.RA2nf7NY02Ddt9Mkv5LxXcWJcFFnmCtfVz3VbpD3Vwv6U130_assertion description "[We have recently shown that a novel, reversible MetAP2 inhibitor, A-357300, significantly inhibits CHP-134-derived neuroblastoma s.c. xenograft growth rate with a treatment-to-control (T/C) ratio at day 24 of 0.19 (P < 0.001) without toxicity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP863646.RA2nf7NY02Ddt9Mkv5LxXcWJcFFnmCtfVz3VbpD3Vwv6U130_provenance.